Tocilizumab improves 28-day survival in hospitalized patients with severe COVID-19: an open label, prospective study.
Karampitsakos T, Malakounidou E, Papaioannou O, Dimakopoulou V, Zarkadi E, Katsaras M, Tsiri P, Tsirikos G, Georgiopoulou V, Oikonomou I, Davoulos C, Velissaris D, Sampsonas F, Marangos M, Akinosoglou K, Tzouvelekis A.
Karampitsakos T, et al. Among authors: marangos m.
Respir Res. 2021 Dec 22;22(1):317. doi: 10.1186/s12931-021-01914-6.
Respir Res. 2021.
PMID: 34937570
Free PMC article.